首站-论文投稿智能助手
典型文献
Persistently low CD4 cell counts are associated with hepatic events in HCV/HIV coinfected patients: data from the national free antiretroviral treatment program of China
文献摘要:
Background::Chronic liver disease has emerged as a leading cause of non-acquired immune deficiency syndrome (AIDS)-related mortality in hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected patients. The relationship between CD4 cell count and HIV-related opportunistic infections and tumors has been well characterized; however, it is unclear whether CD4 cell count is associated with HCV-related hepatic events.Methods::This observational cohort study enrolled HCV/HIV-coinfected patients from the National Free Antiretroviral Treatment Program of China from 2004 to 2019 in Guangzhou. The primary outcome was a composite of hepatic events, including cirrhosis complications, hepatocellular carcinoma (HCC), and liver-related mortality. Kaplan-Meier survival and multivariate logistic regression analyses were performed.Results::Among the 793 patients, 43 developed hepatic events during a median follow-up of 6.7 years, including 35 cirrhosis complications, 13 HCC cases, and 14 cases of liver-related mortality. The 5-year and 10-year cumulative incidences of hepatic events were 4.2% and 9.3%, respectively. Patients who developed hepatic events had a less satisfactory increase in CD4 cell count, lower peak CD4 (354.5 cells/μL vs. 560.0 cells/μL, P < 0.001), and lower percentage of peak CD4 > 500 cells/μL (30.2% vs. 60.7%, P < 0.001) after the initiation of antiretroviral therapy (ART) than those who did not. The cumulative incidences of hepatic events were higher in patients with lower peak CD4 levels with adjusted odds ratios of 3.96 (95% confidence interval [CI]: 1.51-10.40), 2.25 (95% CI: 0.87-5.86), and 0.98 (95% CI: 0.35-2.74) for patients with peak CD4 at <200 cells/μL, 200-350 cells/μL, and 351 to 500 cells/μL, respectively, relative to those with peak CD4 > 500 cells/μL. Peak CD4 was negatively associated with the risk of hepatic events in a dose-response manner ( P-value for trend = 0.004). Conclusion::Persistently low CD4 cell counts after ART are independently associated with a high risk of hepatic events in HCV/HIV-coinfected patients, highlighting the important role of immune reconstitution in improving liver outcomes.
文献关键词:
CD4 cell count;Co-infection;Hepatic events;Hepatitis C virus;Human immunodeficiency virus
作者姓名:
Lin Weiyin;Zhong Huolin;Wen Chunyan;He Yaozu;Zheng Xiaowen;Li Hong;Chen Xiejie;He Haolan;Chen Jinfeng;Chen Lijuan;Liu Cong;Tang Xiaoping;Cai Weiping;Li Linghua
作者机构:
Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China
引用格式:
[1]Lin Weiyin;Zhong Huolin;Wen Chunyan;He Yaozu;Zheng Xiaowen;Li Hong;Chen Xiejie;He Haolan;Chen Jinfeng;Chen Lijuan;Liu Cong;Tang Xiaoping;Cai Weiping;Li Linghua-.Persistently low CD4 cell counts are associated with hepatic events in HCV/HIV coinfected patients: data from the national free antiretroviral treatment program of China)[J].中华医学杂志(英文版),2022(22):2699-2705
A类:
Persistently,coinfected
B类:
CD4,counts,are,associated,hepatic,events,HCV,HIV,patients,data,from,national,free,antiretroviral,treatment,program,China,Background,Chronic,liver,disease,has,emerged,leading,cause,acquired,immune,syndrome,AIDS,related,mortality,hepatitis,virus,human,immunodeficiency,relationship,between,opportunistic,infections,tumors,been,well,characterized,however,unclear,whether,Methods,This,observational,cohort,study,enrolled,National,Free,Antiretroviral,Treatment,Program,Guangzhou,primary,was,composite,including,cirrhosis,complications,hepatocellular,carcinoma,HCC,Kaplan,Meier,survival,multivariate,logistic,regression,analyses,were,performed,Results,Among,developed,during,median,follow,up,years,cases,cumulative,incidences,respectively,Patients,who,had,less,satisfactory,increase,lower,peak,cells,L ,percentage,after,initiation,therapy,ART,than,those,did,not,higher,levels,adjusted,odds,ratios,confidence,interval,relative,Peak,negatively,risk,dose,response,manner,value,trend,Conclusion,independently,highlighting,important,role,reconstitution,improving,outcomes,Hepatic,Hepatitis,Human
AB值:
0.47509
相似文献
Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study
Jia Jingya;Zhu Qiuying;Deng Luojia;Lan Guanghua;Johnson Andrew;Chen Huanhuan;Shen Zhiyong;Li Jianjun;Xing Hui;Ruan Yuhua;Li Jing;Lu Hui;Vermund Sten H.;Zhu Jinhui;Qian Han-Zhu-SJTU-Yale Joint Center for Biostatistics and Data Science, Shanghai Jiao Tong University, Shanghai, China;Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China;Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, China;Groton School, Groton, MA, USA;State Key Laboratory of Infectious Disease Prevention and Control (SKLID), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China;School of Public Health, Yale University, New Haven, CT, USA
Efficacy and safety of Mianyi granules(免疫Ⅱ颗粒)for reversal of immune nonresponse following antiretroviral therapy of human immunodeficiency virus-1:a randomized,double-blind,multi-center,placebo-controlled trial
LIU Ying;ZOU Wen;XIAN Qingfei;DENG Xin;ZHANG Fuchun;WANG Li;LI Yonghong;LUN Wenhui;WANG Jian-Traditional Chinese Medicine Center for Acquired Immune Deficiency Syndrome Prevention and Treatment,China Academy of Chinese Medical Sciences,Beijing 100700,China;Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530011,China;Infectious Disease Department of Guangzhou Eighth People's Hospital,Guangzhou 510060,China;Internal Medicine Department of Traditional Chinese Medicine,Yunnan Provincial Academy of Traditional Chinese Medicine,Kunming 650031,China;Department of Hepatology,Shenyang Sixth People's Hospital,Shenyang 110006,China;Department of Dermatology,Beijing Ditan Hospital,Beijing 100015,China
Wenshen Jianpi recipe(温肾健脾方)induced immune reconstruction and redistribution of natural killer cell subsets in immunological non-responders of human immunodeficiency virus/acquired immune deficiency syndrome:a randomized controlled trial
TAO Zhuang;WANG Jian;CHEN Xin;LI Yonghong;YAN Yuguang;ZHANG Ao;ZOU Wen;LIU Ying-Research Center of AIDS Treatment with Traditional Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Institute of Basic Theory for Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Department of Integrated Traditional Chinese and Wetern Medicine,Kunming Hospital of Traditional Chinese Medicine,Kunming 650000,China;Department of Infection,No.6 People's Hospital of Shenyang City,Shenyang 110006,China;University of Chinese Academy of SoCIal SCIences,Beijing,100102,China
Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail
Chen Nan;Xing Changying;Niu Jianying;Liu Bicheng;Fu Junzhou;Zhao Jiuyang;Ni Zhaohui;Wang Mei;Liu Wenhu;Zhao Jinghong;Zhong Ling;Wu Xiongfei;Li Wenge;Chen Yuqing;Shi Wei;Chen Jianghua;Yin Aiping;Fu Ping;Wang Rong;Jiang Gengru;Hou Fanfan;Ding Guohua;Chen Jing;Xu Gang;Kondo Yuichiro;Su Yuliang;Mei Changlin-Department of Nephrology, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Nephrology, Jiangsu Provincial Hospital, Nanjing, Jiangsu 210036, China;Department of Nephrology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China;Department of Nephrology, Zhongda Hospital Southeast University, Nanjing, Jiangsu 210009, China;Department of Nephrology, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, China;Department of Nephrology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China;Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200001, China;Department of Nephrology, Peking University People's Hospital, Beijing 100044, China;Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Department of Nephrology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China;Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;Department of Nephrology, Southwest Hospital of Army Medical University, Chongqing 400039, China;Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China;Department of Nephrology, Peking University First Hospital, Beijing 100034, China;Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, China;Department of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China;Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Nephrology, Shandong Provincial Hospital, Jinan, Shandong 250021, China;Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Department of Nephrology, Nanfang Hospital Southern Medical University, Guangzhou, Guangdong 510510, China;Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China;Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China;Department of Nephrology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;R&D Planning Department, R&D Division, Kyowa Kirin Co., Ltd, Tokyo 520-5292, Japan;D&R office, Kyowa Kirin China Pharmaceutical Co., Ltd, Shanghai 201203, China;Department of Nephrology, Shanghai Changzheng Hospital, Shanghai 200003, China
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
A multi-center, open-label, randomized, parallel-controlled phase Ⅱ study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera?) in patients with CD20-positive B-cell non-Hodgkin lymphoma
Xiaohong Han;Mingzhi Zhang;Huaqing Wang;Qingyuan Zhang;Wei Li;Miaowang Hao;Yuhuan Gao;Jie Jin;Hanyun Ren;Yun Tang;Xiaonan Hong;Xiaoyan Ke;Hang Su;Lin Gui;Jianmin Luo;Liangzhi Xie;Wenlin Gai;Yuankai Shi-Clinical Pharmacology Research Center,Peking Union Medical College Hospital,State Key Laboratory of Complex Severe and Rare Diseases,NMPA Key Laboratory for Clinical Research and Evaluation of Drug,Beijing Key Laboratory of Clinical PK&PD Investigation for Innovative Drugs,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Medical Oncology,Tianjin People's Hospital,Tianjin 300121,China;Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Oncology Department of Cancer Center,the First Hospital of Jilin University,Changchun 130021,China;Department of Hematology,Tangdu Hospital,Air Force Medical University,Xi'an 710038,China;Department of Hematology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Hematology,the First Affiliated Hospital of Zhejiang University,Hangzhou 310003,China;Department of Hematology,Peking University First Hospital,Beijing 100034,China;Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Medical Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Lymphoma,the Fifth Medical Center of PLA General Hospital,Beijing 100071,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Department of Hematology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Beijing Engineering Research Center of Protein and Antibody,Sinocelltech Ltd.,Beijing 100176,China
Association of baseline hemoglobin A1c levels with bleeding in patients with non-ST-segment elevation acute coronary syndrome underwent percutaneous coronary intervention:insights of a multicenter cohort study from China
Hua-Lin FAN;Li-Huan ZENG;Peng-Yuan CHEN;Yuan-Hui LIU;Chong-Yang DUAN;Wen-Fei HE;Ning TAN;Ji-Yan CHEN;Peng-Cheng HE-Department of Cardiology,School of Medicine,South China University of Technology,Guangzhou,China;Department of Cardiology,Guangdong Cardiovascular Institute,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China;Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China;The Second School of Clinical Medicine,Southern Medical University,Guangzhou,China;Department of Cardiology,the Second People's Hospital of Nanhai District,Guangdong Provincial People's Hospital's Nanhai Hospital,Foshan,China;De-partment of Biostatistics,School of Public Health,Southern Medical University,Guangzhou,China;Department of Cardiology,Heyuan People's Hospital,Heyuan,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。